氟西汀联合利培酮治疗抑郁症的对照研究

A Control study on combination of fluoxetine and risperidone in the treament of depression

目的 探讨氟西汀联合利培酮治疗抑郁症的疗效与安全性。方法 将 6 8例住院抑郁症患者随机分为两组 ,研究组(氟西汀联合利培酮治疗 ) 36例 ,对照组 (单用氟西汀治疗 ) 32例 ,疗程 6w ,于治疗前和治疗 1、2、4、6w末分别采用HAMD、HAMA、CGI SI、TESS评定疗效和不良反应。结果 治疗 6w末 ,两组HAMD、HAMA评分均低于治疗前 ,有极显著性差异 (t=8.7～ 14 .2 ,P <0 .0 1) ;两组间治疗第 4、6w末HAMD、HAMA评分有极显著性差异 (t=2 .5 5～ 3.78,P <0 .0 5～P <0 .0 1) ;研究组有效率 86 % ,对照组有效率 6 2 % ,两组有显著性差异 (χ2 =5 .0 4 ,P <0 .0 5 ) ;两组间不良反应发生率无显著性差异 (χ2=1.0 1,P >0 .0 5 )。结论 氟西汀联合利培酮治疗抑郁症疗效好 。

Objective To explore curative effects and safety of combination of fluoxetine and risperidone in the treatment of depression. Methods 68 in-patients with depression were randomly assigned to research group (combination of fluoxetine and risperidone, n=36) and control group (single fluoxetine, n=32) for 6 weeks. The curative effects and adverse reactions were assessed with HAMD, HAMA,CGI-SI and TESS before treatment and at the ends of the 1^(st),2^(nd),4^(th), 6^(th) week of treatment respectively. Results The scores of HAMD,HAMA were significantly lower after 6 week treatment than before treatment (t=8.7～14.2,P<0.01);The scores of HAMD and HAMA between the 2 groups had significant difference in the 4^(th) and 6^(th) week (t=2.55～3.78,P<0.05～P<0.01); effective rates were 86% of research group and 62% of control group, which showed significant difference (χ~2=5.04,P<0.05);There was no difference in adverse reactions between the two groups (χ~2=1.01,P>0.05). Conclusion Combination of fluoxetine and risperidone is effective and safe in the treatment of depression.